Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

Bryan Oronsky¹, Corey Carter², Anna Scicinska¹, Arnold Oronsky³, Neil Oronsky⁴, Michelle Lybeck¹ and Jan Scicinski¹

¹ EpicentRx, Inc., Mountain View, CA, USA
² Walter Reed National Military Medical Center, Bethesda, MD, USA
³ InterWest Partners, Menlo Park, CA, USA
⁴ CFLS, LLC, San Jose, CA, USA

Correspondence to: Bryan Oronsky, email: boronsky@epicentrx.com

Keywords: cancer, adverse events, risk to benefit, medical machiavellianism

Received: August 15, 2015  Accepted: January 17, 2016  Published: January 22, 2016

ABSTRACT

Machiavellianism is a word synonymous with the phrase “the end justifies the means”, and in this article we have coined the term Medical Machiavellianism to describe the ‘cruel-to-be-kind’ administration of toxic chemotherapeutic agents in apparent violation of the precept first do no harm, while acknowledging the ‘dirty hands’ dilemma of having to decide between and choose the lesser of two evils in the setting of advanced cancer—i.e. to treat or not to treat. The perception that ‘targeted’ therapies are relatively non-toxic and therefore respect the Hippocratic First Commandment by virtue of their narrow selectivity is belied by their often inherent promiscuity, addressing multiple targets either inadvertently or deliberately, which may result in multiple side effects.

The remarkable success of immunotherapy may have taken the bloom off the ‘targeted agent’ rose, however due to a lack of other approved treatment alternatives the toxicity of these agents may be overlooked or, at least, undervalued, especially given that the official measure of treatment success in oncology is overall survival (OS), not quality-of-life improvements.

By analogy with the MACH-IV personality survey (1970), [1] which measures high and low Machiavellian orientation, we have defined in this article a rudimentary MACH scale for selected targeted chemotherapies, based on the means-to-ends ratio of toxicity and benefit. It is our hope that this comparison between targeted agents will itself function as a means to an end—to help oncologists strike the right balance between efficacy, toxicity and quality of life in the management of their patients.

INTRODUCTION

Irrespective of the clinical scenario the guiding principles of medical treatment are “primum non nocere” (“first do no harm”) and “primum succurre” (“first hasten to help”) although in the management of cancer under the rubric of disease eradication the severe toxicities of potentially life-saving chemotherapies may and in fact usually do constitute an acceptable level of harm in apparent violation of the First Golden Rule.

It is a uniformly accepted oncologic tenet that, whatever the prognosis, even if the intent is only palliative, overall survival matters above all else [2, 3]. In other words, from the perspective of the medical establishment, for the sake of an overriding just goal, namely, to postpone the existential threat of cancer, the end justifies the means. This in essence is a form of Medical Machiavellianism (MM), an epithet that originates from the name of Niccolo Machiavelli, the author of the 1513 political treatise, Il Principe, The Prince. This work, a handbook for despots and tyrants on the use of deceptive, manipulative, and ruthless self-serving practices to gain, hold, and expand power, is clearly antithetical to the Hippocratic tradition of beneficent and unselfish concern for the rights and welfare of patients. For Machiavelli
“by any means necessary” was a morally permissible and practically expedient formula because the only virtue is success, no matter the methods necessary to achieve it. Taking inspiration from the work of Richard Christie and Florence Geis [1], who co-opted the term Machiavellianism, a byword for sneakiness, ambition, ruthlessness, and the open espousal of ‘playing hardball’, to describe a constellation of personality traits from which the MACH-IV personality scale was developed in 1970, we have similarly applied the Machiavelli premise of “by any means necessary” to highlight the tradeoffs between activity and adverse events in the treatment of cancer. However, as previously mentioned, Machiavellianism in its original intent is associated with deception, while the practice of medicine, in accordance with the Hippocratic oath and the Hippocratic tradition, should contain no element of deception. In this non-maleficent medical context, since physicians are honor and duty-bound to protect and serve the patient to the exclusion of third-party interests, including their own, MM, rather than implying any element of sham or deceit, is a therapeutic doctrine consistent with “I must be cruel to be kind” and “if it works, use it” because the benefit of overall survival balances or even outweighs considerations related to quality of life and/or cost.

Survival is the name of the game and in the evolving gambit-counter-gambit-counter-gambit chess match of palliative cancer treatment where the oncologist selects a therapy and tumors ‘choose’ an adaptive strategy the sacrifice pawn is invariably quality of life even when the only objective, the best case scenario, is to force a stalemate from an otherwise desperate and hopeless situation. Nevertheless in reaction to the broad toxicities of conventional chemotherapy therapeutic strategies have evolved to only target cancer cells while sparing their normal counterparts (in what might be called somewhat facetiously primum non chemothere). However, even in this era of personalized medicine, where particular therapies are designed and developed for particular patients, based on a pharmacogenomic likelihood of benefit, the balance of antitumor activity versus toxicity is—or should be—a critical consideration.

While the applicability of this personalization on a general level remains at best an open question, it should be noted that the term “targeted” therapy is largely a misnomer since the most active molecular therapeutics (e.g. small molecule tyrosine kinase inhibitors [4] are more promiscuous than selective with multiple confirmed molecular targets (e.g. imatinib). And, in some cases, unintended ‘off-target’ effects may be clinically significant, such as inhibition of vascular endothelial growth factor receptor 2 (VEGFR2) with regorafenib [5].

The equation, ‘drug + molecular target = targeted therapy’, with its implication of narrow biological specificity and toxicity, almost certainly oversimplifies the enormously complex and coordinated interactions that occur in vivo [5]. The analogy of Ehrlich’s magic bullet applies to targeted therapies but only in the sense of a ricocheting bullet simultaneously hitting multiple targets.

The term targeted therapy also implies, incorrectly, that conventional chemotherapy is untargeted. In fact, all clinical chemotherapy, regardless of the mechanism, by virtue of exercising selective cytotoxicity has a target on which it acts [6], even if that target isn’t known or understood. However, when advanced tumors are confronted with targeted or “untargeted” chemotherapies, alone or in combination, the result is almost always the same—acquired resistance.

Nevertheless, as targeted therapies [7] become the blueprint and the prevalent paradigm in drug development and clinical oncology, there is a danger that oncologists will overestimate the role of these therapies and, at the same time, undervalue the impact of their toxicity. Lamentably, because quality of life is not generally assessed in clinical trials as an approval endpoint, targeted chemotherapies in general cannot be properly evaluated from a benefit-toxicity perspective.

METHODS AND RESULTS

By analogy with a survey in neuropsychology called MACH-IV by Christie and Geis in 1970 [1, 8], which measures Machiavellianism as a distinct personality construct, and ranks orientation according to high or low Mach, we have defined a rudimentary MACH scale for targeted chemotherapies, based on the means-to-ends ratio of toxicity and benefit, derived from a Phase 3 registration trial. The adverse event ratio is defined as the ratio of the percentage of Grade 3 and Grade 4 adverse events of the study drug to the comparator:

\[
MACH \text{ Index} = \frac{\text{Adverse Event Ratio}}{\text{Survival Ratio}}
\]

Survival ratio

Where the Adverse Event Ratio is the ratio of the percent of Grade 3 and higher adverse events for the study drug divided by percent of Grade 3 and higher adverse events for the comparator and the Survival ratio is the number of months of median OS for the study drug over the median OS for the comparator in months.

Although comparisons between different agents depend on the type of comparator in the registration trial, with the use of placebo potentially resulting in the highest MACH index, in general, the higher the MACH index the less desirable the agent, at least from a quality of life perspective. In this article we compare the MACH Index for the following small molecule inhibitors: regorafenib (Stivarga), sorafenib (Nexavar), bortezomib (Velcade), erlotinib (Tarceva), and sunitinib (Sutent) (Tables 1 & 2).
Figure 1: Survival and adverse event ratios of selected targeted anti-cancer drugs. Regions are defined as: A. Favorable high survival benefit to low toxicity; B. Balance survival vs. toxicity; C. Unfavorable survival benefit to toxicity.
of the genetic vulnerabilities and dependencies of cancer has not advanced sufficiently to permit development of highly effective molecularly targeted agents with non-
toxic safety profiles, it is anticipated that a new generation of bellwether onco-immunology agents, from checkpoint
inhibitors to oncolytic viruses, currently in development, will usher in a paradigm shift toward region ‘A’ of the
graph.

Although our approach is quite plainly *ad hoc*, subjective, and heavily dependent on the particular disease under investigation as well as the comparator in the clinical trial, we hope the intention to benchmark these ‘targeted’ agents with an easily accessible rating system will serve to highlight the centrality of QOL as a primary index for individual patients rather than relegating it to the all-too-familiar status of mere window dressing or icing on the cake after overall survival.

Finally, while it may seem somewhat shocking and heretical to associate the practice of oncology, an
ostensible ethical and moral good, with Machiavellian tactics, the fact is that in the face of metastatic cancer the absolute standard of non-malfeasance—“do no harm”—does not necessarily apply and tough tradeoff treatment decisions are frequently necessary to extend survival. In this context, it is our hope that this article may help guide oncologists, in true Machiavellian fashion, to choose the lesser of two necessary targeted evils.

**Abbreviations**

- CTLA-4, Cytotoxic T-lymphocyte-associated protein 4; MM, Medical Machiavellianism; OS, Overall survival; PD-1, Programmed cell death protein 1; QOL, Quality of Life; VEGFR2, vascular endothelial growth factor receptor 2.

**ACKNOWLEDGMENTS**

The authors would like to acknowledge and recognize Harry Lybeck, gentleman, scholar, scientist and
physician who at 96 years old continues in daily life, as he
did in his medical practice, to be guided by the precepts of Hippocrates rather than Machiavelli.

**FUNDING**

The authors received no funding in the writing of this manuscript.

**Key Message**

The term “Medical Machiavellianism” is presented along with an original tool to aid oncologists in their selection of treatment for their patients. By analogy with the MACH-IV personality survey (Christie & Geis,
which measures Machiavellian orientation, a rudimentary MACH scale for selected targeted chemotherapies is defined, based on the means-to-ends ratio of toxicity and benefit.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest in the publication of this article.

REFERENCES

1. Christie R, Geis F. Studies in Machiavellianism. NY: Academic Press.; 1970.
2. Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA, Drake CG. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 2010; 21: 1944-51.
3. Pazdur R. Endpoints for assessing drug activity in clinical trials. The oncologist. 2008; 13 Suppl 2: 19-21.
4. Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol. 2011; 2: 80-93.
5. Lee JM, Kohn EC. Proteomics as a guiding tool for more effective personalized therapy. Ann Oncol. 2010; 21 Suppl 7: vii205-10.
6. Vincent MD. The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto. Evolution. 2010; 64: 1173-83.
7. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77: 311-9.
8. Gunnthorsdottir A, McCabe K, Smith V. Using the Machiavellianism instrument to predict trustworthiness in a bargaining game. Journal of Economic Psychology. 2002; 23: 49-66.
9. Huang S. The war on cancer: lessons from the war on terror. Frontiers in oncology. 2014; 4: 293.
10. Oronskey B, Carter CA, Mackie V, Scicinski J, Oronskey A, Oronskey N, Caroen S, Parker C, Lybeck M, Reid T. The war on cancer: a military perspective. Frontiers in oncology. 2014; 4: 387.
11. Kirk R. Targeted therapies: the toxic reality of new drugs. Nat Rev Clin Oncol. 2012; 9: 488.
12. Bouwling A. Measuring Disease. A Review of disease-specific quality of life measurement scales. 2nd ed. Buckingham, UK: Open University Press; 2001.